Personalized Breast Cancer Treatment
1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner, Sara LU ; Ehinger, Anna LU
;
Bendahl, Pär-Ola
LU
;
Rydén, Lisa
LU
and
Fernö, Mårten
LU
(2015)
In European Journal of Cancer
51(16).
p.2304-2313
Mark
-
Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
Alkner, Sara LU ; Tang, Man-Hung Eric LU ; Brueffer, Christian LU
;
Dahlgren, Malin
LU
;
Chen, Yilun
LU
;
Olsson, Eleonor
LU
;
Winter, Christof
LU
;
Baker, Sara
LU
;
Ehinger, Anna
LU
and
Rydén, Lisa
LU
, et al.
(2015)
In Breast Cancer Research
17(1).
Mark
- Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
- Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
- 2013
- A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.
- 2012
- Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
- 2008
- Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
- 2007
-
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
Gruvberger, Sofia LU ; Bendahl, Pär-Ola LU ; Saal, Lao H LU
;
Laakso, Mervi
;
Hegardt, Cecilia
LU
;
Edén, Patrik
LU
;
Peterson, Carsten
LU
;
Malmström, Per
LU
;
Isola, Jorma
LU
and
Borg, Åke
LU
, et al.
(2007)
In Clinical Cancer Research
13(7).
p.1987-1994
Mark
- 2004
- "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers.
- 2001
- S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer